Meta-analysis of the Efficacy of Percutaneous Endocardial Radiofrequency Ablation of Septal Hypertrophy in the Treatment of Hypertrophic Obstructive Cardiomyopathy

doi:10.3870/j.issn.1672-0741.24.07.35

Abstract

Abstract: Objective We conducted a meta-analysis to systematically evaluate the clinical efficacy of endocardial radiofrequency ablation of septal hypertrophy(ERASH)for the treatment of hypertrophic obstructive cardiomyopathy(HOCM). Methods Relevant literature was retrieved from PubMed,the Cochrane Library,Embase,CNKI,VIP and Wanfang Data,with the search period spanning from the inception of each database to June 2024.JBI scale was used to evaluate literature quality.Continuous data were described using weighted mean difference(WMD)and 95% confidence interval(CI).Meta-analysis was performed using Stata 18.0 software. Results A total of 11 singlearm clinical studies involving 231 patients with HOCM were included,with a mean age of 51.27 years.The results of the meta-analysis showed that at the final follow-up after ERASH intervention,the resting and provoked left ventricular outflow tract pressure gradient(LVOTPG)was significantly reduced by 61.13 mmHg[95%CI(40.68,82.58),P<0.01]and 91.91 mmHg[95%CI(71.43,112.39),P<0.01],respectively,compared with preoperative levels.The New York Heart Association(NYHA)functional class at the final follow-up decreased by 1.70[95%CI(1.53,1.88),P<0.01]relative to baseline.In addition,the total 6-minute walking distance at the final follow-up was significantly increased by 103.75 m compared with baseline(95%CI:-167.45,-40.05,P=0.01).Plasma brain natriuretic peptide(BNP)levels were markedly decreased by 786.55 pg/mL at the final follow-up(95%CI:724.50,848.60,P<0.01).Nevertheless,the interventricular septum thickness(IVST)at the final follow-up showed no statistically significant difference compared with baseline(P=0.23).Subgroup analysis based on follow-up duration(6 months vs.over 6 months)demonstrated that ERASH intervention significantly reduced resting LVOTPG and improved 6-minute walking distance in both subgroups(all P<0.01). Conclusion ERASH is effective in the treatment of patients with HOCM.However,further large-scale randomized controlled trials are still required to verify these findings.

Key words: hypertrophic obstructive cardiomyopathy, endocardial radiofrequency ablation of septal hypertrophy, Meta-analysis

CLC Number:

R542.2

Shao Baoxing, Hao Yan, Ma Baoxin. Meta-analysis of the Efficacy of Percutaneous Endocardial Radiofrequency Ablation of Septal Hypertrophy in the Treatment of Hypertrophic Obstructive Cardiomyopathy[J]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong, 2026, 55(3): 400-408.

References

[1] Mehra N,Ali A H,Desai M Y.Obstructive hypertrophic cardiomyopathy:a review of new therapies[J].Future Cardiol,2023,19(13):661-670.
[2] Braunwald E,Saberi S,Abraham T P,et al.Mavacamten:a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy[J].Eur Heart J,2023,44(44):4622-4633.
[3] Liu Q,Qiu H,Jiang R,et al.Selective interventricular septal radiofrequency ablation in patients with hypertrophic obstructive cardiomyopathy:Who can benefit?[J].Front Cardiovasc Med,2021,8:743044.
[4] Kong L,Zhao Y,Pan H,et al.A modified endocardial radiofrequency ablation approach for hypertrophic obstructive cardiomyopathy guided by transthoracic echocardiography:A case series[J].Ann Transl Med,2021,9(12):1006.
[5] Munn Z,Barker T H,Moola S,et al.Methodological quality of case series studies:An introduction to the JBI critical appraisal tool[J].JBI Evid Synth,2020,18(10):2127-2133.
[6] von Hippel P T.The heterogeneity statistic I₂ can be biased in small meta-analyses[J].BMC Med Res Methodol,2015,15(1):35.
[7] Lawrenz T,Lawin D,Radke K,et al.Acute and chronic effects of endocardial radiofrequency ablation of septal hypertrophy in HOCM[J].J Cardiovasc Electrophysiol,2021,32(10):2617-2624.
[8] Lawrenz T,Borchert B,Leuner C,et al.Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy acute results and 6 months’follow-up in 19 patients[J].J Am Coll Cardiol,2011,57(5):572-576.
[9] 苏小雅.经皮心内膜室间隔射频消融术对肥厚型梗阻性心肌病患者心功能的影响[D].石家庄:河北医科大学,2022.
Su X Y.Effect of percutaneous endocardial ventricular septal radiofrequency ablation on cardiac function in patients with hypertrophic obstructive cardiomyopathy[D].Shijiazhuang:Hebei Medical University,2022.
[10] 张宏禹.肥厚型梗阻性心肌病患者经皮心内膜室间隔射频消融术的疗效分析[D].石家庄:河北医科大学,2022.
Zhang H Y.Efficacy of percutaneous endocardial septal radiofrequency ablation in patients with hypertrophic obstructive cardiomyopathy[D].Shijiazhuang:Hebei Medical University,2022.
[11] 刘荣.心腔内超声指导下经导管室间隔射频消融治疗肥厚型梗阻性心肌病疗效分析[D].新乡:新乡医学院,2021.
Liu R.Effect analysis on transcatheter septal radiofrequency ablation guided by intracardiac echocardiography in the treatment of hypertrophic obstructive cardiomyopathy[D].Xinxiang:Xinxiang Medical University,2021
[12] 蔡迟,王靖,楚建民,等.心内膜室间隔射频消融治疗肥厚型梗阻性心肌病的疗效分析[J].中国心脏起搏与心电生理杂志,2021,35(4):325-330.
Cai C,Wang J,Chu J M,et al.The efficacy of endocardial radiofrequency ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy[J].Chinese Journal of Cardiac Pacing and Electrophysiology,2021,35(4):325-330.
[13] Valdigem B P,Correia E B,Moreira D A R,et.al.Septal ablation with radiofrequency catheters guided by echocardiography for treatment of patients with obstructive hypertrophic cardiomyopathy:Initial experience[J].Arq Bras Cardiol.,2022,118(5):861-872.
[14] Cooper R M,Shahzad A,Hasleton J,et al.Radiofrequency ablation of the interventricular septum to treat outflow tract gradients in hypertrophic obstructive cardiomyopathy:A novel use of CARTOSound© technology to guide ablation[J].Europace,2016,18(1):113-120.
[15] Sreeram N,Emmel M,de Giovanni J V.Percutaneous radiofrequency septal reduction for hypertrophic obstructive cardiomyopathy in children[J].J Am Coll Cardiol,2011,58(24):2501-2510.
[16] Morrow A G,Brockenbrough E C.Surgical treatment of idiopathic hypertrophic subaortic stenosis:Technic and hemodynamic results of subaortic ventriculomyotomy[J].Ann Surg,1961,154(2):181-189.
[17] Sigwart U.Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy[J].Lancet,1995,346(8969):211-214.
[18] Douglas J S.Current state of the roles of alcohol septal ablation and surgical myectomy in the treatment of hypertrophic obstructive cardiomyopathy[J].Cardiovasc Diagn Ther,2020,10(1):36-44.
[19] Sorajja P,Fraser R,Steffen R,et al.Alcohol septal ablation for obstructive hypertrophic cardiomyopathy[J].Interv Cardiol Clin,2022,11(3):245-255.
[20] Lawrenz T,Kuhn H.Endocardial radiofrequency ablation of septal hypertrophy.A new catheter-based modality of gradient reduction in hypertrophic obstructive cardiomyopathy[J].Z Kardiol,2004,93(6):493-499.
[21] Poon S S,Cooper R M,Gupta D.Endocardial radiofrequency septal ablation—a new option for non-surgical septal reduction in patients with hypertrophic obstructive cardiomyopathy(HOCM)?:A systematic review of clinical studies[J].Int J Cardiol,2016,222:772-774.
[22] Jiang T,Huang B,Huo S,et al.Endocardial radiofrequency ablation vs.septal myectomy in patients with hypertrophic obstructive cardiomyopathy:A systematic review and meta-analysis[J].Front Surg,2022,9:859205.
[23] Liu Y,Song Y,Gao G,et al.Outcomes of an extended Morrow procedure without a concomitant mitral valve procedure for hypertrophic obstructive cardiomyopathy[J].Sci Rep,2016,6:29031.
[24] Nagueh S F,Groves B M,Schwartz L,et al.Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy a multicenter North American registry[J].J Am Coll Cardiol,2011,58(22):2322-2328.